1) 日本腎臓病学会, 編. エビデンスに基づくCKD診療ガイドライン. 東京医学社 ; 2018. <https://cdn.jsn.or.jp/>
2) 日本腎臓学会, 編. 慢性腎臓病に対する食事療法基準 2014年版. 東京医学社 ; 2014. <https://cdn.jsn.or.jp/>
3) Zerniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes : a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 ; 393 : 31-9.
4) Heerspink HJL, Stefansson BV, Correa-Rotter R, et al ; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 ; 383 : 1436-46.
5) CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N Engl J Med. 1987 ; 316 : 1429-35.
6) Edner M, Benson L, Dahlstrom U, et al. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency : a prospective propensity scorematched cohort study. Eur Heart J. 2015 ; 36 : 2318-26.
7) Wali RK, Lyengar M, Beck G, et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease : A meta-analysis of randomized trials Circ Heart Fail. 2011 ; 4 : 18-26.
8) Tang CH, Wang CC, Chen TH, et al. Prognostic benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release in hemodialysis patients with heart failure : A 10-year cohort. J Am Heart Assoc. 2016 ; 5 : e002584.
9) Vardeny O, Wu DH, Desai A, et al ; RALES Investigators. Influence of baseline and worsening renal function on efficacy of spironolactonein patients with severe heart failure : insights from RALES (Randomized Aldactone Evaluation Study), J Am Coll Cardiol. 2012 ; 60 : 2082-9.
10) Eschalier R, McMurray JJV, Swedberg K, et al ; EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function : analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure), J Am Coll Cardiol. 2013 ; 62 : 1585-93.
11) Damman K, Gori M, Claggett B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018 ; 6 : 489-98.
12) Kang H, Zhang J, Zhang X, et al. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease : A meta-analysis. Eur J Pharmacol. 2020 ; 884 : 173444.
13) Inomata T, Ikeda Y, Kida K, et al. Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment-results from the K-STAR Study. Circ J. 2017 ; 82 : 159-67.